(Q38112976)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

HPV vaccine cross-protection: Highlights on additional clinical benefit (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Caterina Ricci

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

4

Giovanni Scambia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Carmine Conte

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

5 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

642-651

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Potential mechanisms for HPV vaccine-induced long-term protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

The carcinogenicity of human papillomavirus types reflects viral evolution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Measuring serum antibody to human papillomavirus following infection or vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Immunological events in regressing genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Immune responses to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Cross-protection is crucial for prophylactic HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

The viral etiology of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.033

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2013.05.033

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23747835%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference